Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Sangamo Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R1D vs SER, ABVC, PLRZ: OCF Margin % Comparison
For the Biotechnology subindustry, Sangamo Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangamo Therapeutics OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sangamo Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangamo Therapeutics (LTS:0R1D) has a OCF Margin % of -1,337.17% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sangamo Therapeutics and its competitors. According to the industry distribution chart, Sangamo Therapeutics ranks #617 out of 953 companies in the Biotechnology industry, placing it in the top 64.7%.
Is Sangamo Therapeutics' OCF Margin % too high?
Sangamo Therapeutics' current OCF Margin % is -1,337.17%. Based on the distribution chart, Sangamo Therapeutics ranks #617 out of 953 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sangamo Therapeutics has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sangamo Therapeutics' OCF Margin % compare to SER and ABVC?
According to the Biotechnology industry distribution chart, Sangamo Therapeutics ranks #617 out of 953 companies for OCF Margin %. This places Sangamo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sangamo Therapeutics and its competitors. Sangamo Therapeutics's current OCF Margin % is -1,337.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sangamo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sangamo Therapeutics (LTS:0R1D) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.11 — trading 42.2% below its estimated fair value. The current OCF Margin % is -1,337.17%. Sangamo Therapeutics' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sangamo Therapeutics (LTS:0R1D), the current OCF Margin % is -1,337.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?
Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued.
The current stock price of $0.11 is trading 42.2% below its estimated GF Value™ of $0.19.
GuruFocus considers Sangamo Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0R1D:
OCF Margin %: -1,337.17%
GF Value™: $0.19 vs. price of $0.11 (42.2% below fair value)
No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
35GF Score
Get the complete analysis for LTS:0R1D
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R1D has been successfully added to your 
